Cortexin vs N-Acetyl Semax

Polypeptide bioregulator from bovine cortex; modulates neurotransmitter activity; activates GABA and dopamine systems; reduces excitotoxicity; stimulates neuronal repair

Cortexin is a polypeptide bioregulator derived from porcine cerebral cortex, used clinically in Russia and Eastern Europe as a neuroprotective and nootropic agent for stroke, traumatic brain injury, and chronic cerebrovascular disorders. It contains a complex mixture of tissue-specific neuropeptides, amino acids, and microelements proposed to support neuronal survival, reduce excitotoxic damage, and promote neurotrophic factor expression in injured brain tissue. Russian clinical trials have examined cortexin in acute ischemic stroke rehabilitation and other neurological conditions, with results suggesting potential benefit in functional recovery, though studies are predominantly published in Russian-language journals with limited methodological transparency by international standards. Cortexin is not FDA-approved; it is a licensed prescription drug in Russia and several post-Soviet states, where it has regulatory approval for neurological indications. Cortexin administration: in clinical settings where it is approved, cortexin is administered by intramuscular injection, typically as a 10 mg dose reconstituted in saline or procaine. Clinical courses in Russian practice involve daily injections over 10-day cycles, repeated 1–2 times per year for chronic neurological conditions. This administration pattern is common to several Russian polypeptide bioregulators, including cerebrolysin — another porcine-derived peptide mixture with a broader international clinical trial dataset — and cortagen, a cardiac-focus bioregulator from the same pharmacological class. Cortexin is the cerebral-cortex-specific member of this class; cortagen targets cardiovascular tissue, and thymalin targets thymic/immune tissue. Provider availability for cortexin outside Russia is limited compared to peptides with international regulatory approvals; it is occasionally carried by compounding pharmacies and specialized nootropic suppliers. The PeptideBase cognitive peptides directory lists verified providers who carry neuroprotective peptide compounds.

Same ACTH(4-7) core as Semax, but structural modifications resist peptidase degradation. Enhances BDNF expression, supports dopaminergic and serotonergic neurotransmission, and modulates NMDA receptor activity.

N-Acetyl-Semax is an acetylated derivative of semax (MEHFPGP), the synthetic ACTH(4-7)PGP heptapeptide nootropic and neuroprotective compound developed in Russia; N-acetylation is proposed to improve enzymatic stability and CNS pharmacokinetics relative to the parent compound, with the expectation that the acetylated form retains semax receptor interactions and neurotrophic effects with potentially greater bioavailability. Semax itself modulates BDNF and NGF expression, influences dopaminergic and serotonergic activity, and has been studied in Russian clinical trials for ischemic stroke and cognitive disorders; N-acetyl-semax is marketed as an enhanced analog on the basis of these parent compound properties. No publications indexed in PubMed specifically examine N-acetyl-semax as a distinct compound; no human clinical trials, independent preclinical studies, or pharmacokinetic data for this specific acetylated form appear in the indexed scientific literature, meaning all claims about this compound are extrapolations from the parent compound evidence base. N-Acetyl-Semax has no FDA approval and no approved indication in any jurisdiction; it is available through research chemical suppliers as an analog of a Russia-approved compound, but its independent pharmacological properties and human safety profile are entirely uncharacterized as a distinct molecule. Semax variant landscape: N-Acetyl-Semax sits alongside several related analogs in the research compound market. The base compound semax (approved in Russia, primarily used intranasally) is the most evidence-backed form. Semax amidate and N-acetyl semax amidate add C-terminal amidation — another stability modification proposed to further reduce enzymatic cleavage. Research suppliers sometimes list "N-Acetyl Semax Amidate" as a combined modification compound. All variant claims trace back to the parent semax pharmacology; independent validation of each structural modification's effect on human CNS pharmacokinetics does not exist in published literature. Administration: N-Acetyl-Semax is most commonly used as a nasal spray solution, mirroring the intranasal route of approved semax in Russia. This route is proposed to allow absorption via the olfactory epithelium for partial CNS delivery. Cognitive peptide providers offering semax-class compounds are listed in the PeptideBase cognitive peptides directory.